Your guide to biotech’s next big news

Is Mirati Therapeutics overrated? Can Sage Therapeutics keep up its momentum? And how will the Amarin saga conclude?

We’re going to learn all that and more in the coming months, and, to keep from getting blindsided by major biotech news, STAT’s Adam Feuerstein put together a scorecard of the biggest expected happenings in the fourth quarter.

If everything goes as expected, there’ll be sizable news in the fields of depression, oncology, genome editing, and rare disease.

Read more.